Countries are at different stages of introducing already approved PrEP, and more PrEP products are coming. Some countries have national programs, others have smaller-scale programs, others aren’t yet offering PrEP at all. In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not. In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not.
Want to take the next step in expanding access to PrEP? Check out PrEP Planning A-Z.
This framework outlines the steps involved to introduce oral PrEP as a model for scaling up biomedical HIV prevention products—with links to tools and resources.
Two views of PrEP uptake around the world: The PrEP Tracker as data visualization—a dynamic map exploring global trends
The PrEP Tracker in Excel—details on the full scope of programs in every country
A living document serving as a consolidated map describing current and planned activities at the global level to support ring introduction.
Stories from implementers rolling out PrEP: a look at some real world obstacles and the tools and insights to overcome them.
AVAC enthusiastically welcomes the South African Health Products Regulatory Authority’s (SAHPRA) approval of the monthly Dapivirine Vaginal Ring for use by women ages 18 and older to reduce their HIV risk.
The US Food and Drug Administration (FDA) approved Apretude, or extended-release cabotegravir, as the first long-acting injectable option for HIV pre-exposure prophylaxis (PrEP).